Cartesian Therapeutics, Inc. (RNAC) Investor Relations Documents

Cartesian Therapeutics, Inc. (RNAC) investor relations documents from the company's IR site: 1 presentation, 29 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

August 2026 Corporate Presentation: Cartesian Therapeutics is pioneering mRNA cell therapy for autoimmunity, with Descartes-08 showing deep and durable Myasthenia Gravis responses, targeting a $1B+ market.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releasePDF Version
2026-08-07Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
2026-08-06Press releasePDF Version
2026-08-06Press releaseCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05PresentationAugust 2026 Corporate Presentation
2026-07-02Press releasePDF Version
2026-07-02Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
2026-06-12Press releasePDF Version
2026-06-12Press releaseCartesian Therapeutics Announces New Employment Inducement Grant
2026-06-09Press releasePDF Version
2026-06-09Press releaseCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of
2026-05-26Press releasePDF Version
Press releaseCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline D
2026-05-12Press releasePDF Version
2026-05-12Press releaseCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-04Press releasePDF Version
2026-05-04Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
2026-04-30Press releasePDF Version
2026-04-30Press releaseCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-02Press releasePDF Version
2026-04-02Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
2026-03-09Press releasePDF Version
2026-03-09Press releaseCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
2026-02-23Press releaseCartesian Therapeutics to Participate in Upcoming Investor Conferences
2026-02-03Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
2026-01-09Press releaseCartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
2026-01-06Press releaseCartesian Therapeutics Announces New Employment Inducement Grants
Press releaseCartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Press releaseCartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Press releaseCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

RNAC overview · RNAC earnings · RNAC financials · RNAC KPIs · RNAC ownership · RNAC peers · RNAC filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.